Comparison of Protein and Peptide Targeting for the Development of a CD169-Based Vaccination Strategy Against Melanoma

Dieke van Dinther, Henrike Veninga, Mirjam Revet, Leoni Hoogterp, Katarzyna Olesek, Joanna Grabowska, Ellen G F Borg, Hakan Kalay, Yvette van Kooyk, Joke M M den Haan

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

CD169+ macrophages are part of the innate immune system and capture pathogens that enter secondary lymphoid organs such as the spleen and the lymph nodes. Their strategic location in the marginal zone of the spleen and the subcapsular sinus in the lymph node enables them to capture antigens from the blood and the lymph respectively. Interestingly, these specific CD169+ macrophages do not destroy the antigens they obtain, but instead, transfer it to B cells and dendritic cells (DCs) which facilitates the induction of strong adaptive immune responses. This latter characteristic of the CD169+ macrophages can be exploited by specifically targeting tumor antigens to CD169+ macrophages for the induction of specific T cell immunity. In the current study we target protein and peptide antigen as antibody-antigen conjugates to CD169+ macrophages. We monitored the primary, memory, and recall T cell responses and evaluated the anti-tumor immune responses after immunization. In conclusion, both protein and peptide targeting to CD169 resulted in strong primary, memory, and recall T cell responses and protective immunity against melanoma, which indicates that both forms of antigen can be further explored as anti-cancer vaccination strategy.

LanguageEnglish
Pages1997
JournalFrontiers in Immunology
Volume9
DOIs
Publication statusPublished - 2018

Cite this

@article{b762f39c4dfa4ccf8d189110816bfc90,
title = "Comparison of Protein and Peptide Targeting for the Development of a CD169-Based Vaccination Strategy Against Melanoma",
abstract = "CD169+ macrophages are part of the innate immune system and capture pathogens that enter secondary lymphoid organs such as the spleen and the lymph nodes. Their strategic location in the marginal zone of the spleen and the subcapsular sinus in the lymph node enables them to capture antigens from the blood and the lymph respectively. Interestingly, these specific CD169+ macrophages do not destroy the antigens they obtain, but instead, transfer it to B cells and dendritic cells (DCs) which facilitates the induction of strong adaptive immune responses. This latter characteristic of the CD169+ macrophages can be exploited by specifically targeting tumor antigens to CD169+ macrophages for the induction of specific T cell immunity. In the current study we target protein and peptide antigen as antibody-antigen conjugates to CD169+ macrophages. We monitored the primary, memory, and recall T cell responses and evaluated the anti-tumor immune responses after immunization. In conclusion, both protein and peptide targeting to CD169 resulted in strong primary, memory, and recall T cell responses and protective immunity against melanoma, which indicates that both forms of antigen can be further explored as anti-cancer vaccination strategy.",
author = "{van Dinther}, Dieke and Henrike Veninga and Mirjam Revet and Leoni Hoogterp and Katarzyna Olesek and Joanna Grabowska and Borg, {Ellen G F} and Hakan Kalay and {van Kooyk}, Yvette and {den Haan}, {Joke M M}",
year = "2018",
doi = "10.3389/fimmu.2018.01997",
language = "English",
volume = "9",
pages = "1997",
journal = "Frontiers in Immunology: Molecular Innate Immunity",
issn = "1664-3224",
publisher = "Frontiers Media S.A.",

}

Comparison of Protein and Peptide Targeting for the Development of a CD169-Based Vaccination Strategy Against Melanoma. / van Dinther, Dieke; Veninga, Henrike; Revet, Mirjam; Hoogterp, Leoni; Olesek, Katarzyna; Grabowska, Joanna; Borg, Ellen G F; Kalay, Hakan; van Kooyk, Yvette; den Haan, Joke M M.

In: Frontiers in Immunology, Vol. 9, 2018, p. 1997.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Comparison of Protein and Peptide Targeting for the Development of a CD169-Based Vaccination Strategy Against Melanoma

AU - van Dinther, Dieke

AU - Veninga, Henrike

AU - Revet, Mirjam

AU - Hoogterp, Leoni

AU - Olesek, Katarzyna

AU - Grabowska, Joanna

AU - Borg, Ellen G F

AU - Kalay, Hakan

AU - van Kooyk, Yvette

AU - den Haan, Joke M M

PY - 2018

Y1 - 2018

N2 - CD169+ macrophages are part of the innate immune system and capture pathogens that enter secondary lymphoid organs such as the spleen and the lymph nodes. Their strategic location in the marginal zone of the spleen and the subcapsular sinus in the lymph node enables them to capture antigens from the blood and the lymph respectively. Interestingly, these specific CD169+ macrophages do not destroy the antigens they obtain, but instead, transfer it to B cells and dendritic cells (DCs) which facilitates the induction of strong adaptive immune responses. This latter characteristic of the CD169+ macrophages can be exploited by specifically targeting tumor antigens to CD169+ macrophages for the induction of specific T cell immunity. In the current study we target protein and peptide antigen as antibody-antigen conjugates to CD169+ macrophages. We monitored the primary, memory, and recall T cell responses and evaluated the anti-tumor immune responses after immunization. In conclusion, both protein and peptide targeting to CD169 resulted in strong primary, memory, and recall T cell responses and protective immunity against melanoma, which indicates that both forms of antigen can be further explored as anti-cancer vaccination strategy.

AB - CD169+ macrophages are part of the innate immune system and capture pathogens that enter secondary lymphoid organs such as the spleen and the lymph nodes. Their strategic location in the marginal zone of the spleen and the subcapsular sinus in the lymph node enables them to capture antigens from the blood and the lymph respectively. Interestingly, these specific CD169+ macrophages do not destroy the antigens they obtain, but instead, transfer it to B cells and dendritic cells (DCs) which facilitates the induction of strong adaptive immune responses. This latter characteristic of the CD169+ macrophages can be exploited by specifically targeting tumor antigens to CD169+ macrophages for the induction of specific T cell immunity. In the current study we target protein and peptide antigen as antibody-antigen conjugates to CD169+ macrophages. We monitored the primary, memory, and recall T cell responses and evaluated the anti-tumor immune responses after immunization. In conclusion, both protein and peptide targeting to CD169 resulted in strong primary, memory, and recall T cell responses and protective immunity against melanoma, which indicates that both forms of antigen can be further explored as anti-cancer vaccination strategy.

U2 - 10.3389/fimmu.2018.01997

DO - 10.3389/fimmu.2018.01997

M3 - Article

VL - 9

SP - 1997

JO - Frontiers in Immunology: Molecular Innate Immunity

T2 - Frontiers in Immunology: Molecular Innate Immunity

JF - Frontiers in Immunology: Molecular Innate Immunity

SN - 1664-3224

ER -